Home> News> New HARMONY Delphi Survey for #ALL Core Outcome Set open

New HARMONY Delphi Survey for #ALL Core Outcome Set open

January 13, 2022 17:15 - x 00, 0 - 00:00

New treatments for Acute Lymphoblastic Leukemia are currently being tested in studies across the world. Only a few assess the effects of the drugs on patients’ quality of life. In addition, each study uses its own measures to assess whether the treatment works. This makes it difficult to compare and combine studies. It is difficult to draw firm conclusions about which treatments are best.

The HARMONY Alliance is running its 6th Delphi Survey, this time for Acute Lymphoblastic Leukemia (ALL). Our survey aims to identify the most important outcome measures for ALL research.

Patients, clinicians, drug developers and regulators in our network are asked to help determine which outcome measures matter most to ALL patients.

At present, several innovative compounds are being tested in clinical trials in order to improve the treatment of Acute Lymphoblastic Leukemia (ALL). However, these trials measure different outcomes, thus questioning their comparability. In addition, the majority of clinical trials do not assess long-term side effects and their influence on the patients’ quality of life. A core outcome set (COS) may assist researchers in selecting outcomes for future trials, thereby promoting harmonization of ALL studies and improving clinical management of the disease.

Read the full article >

or scan the flyer >

and participate, this is the direct link to the ALL Delphi Survey (https://delphimanager.liv.ac.uk/ALL/Delphi) >

Thank you very much in advance by the HARMONY Alliance Delphi Survey Team

Lars Bullinger, Charité University Medicine Berlin
Katharina Lang, Charité University Medicine Berlin
Renate Schulze-Rath, Bayer
Martje Barbus, AbbVie
Samantha Nier, Acute Leukemia Advocates Network

More information? Send us a message >

#bigdataforbloodcancer: Accelerating Better and Faster Treatment for Patients with Hematologic Malignancies.

The HARMONY Alliance (HARMONY and HARMONY PLUS) is a public-private European Network of Excellence for Big Data in Hematology. Our mission is to unlock and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders, with the goal to harness and mine Big Data to speed up the development of improved treatments for patients and more effective treatment strategies.

Receive the latest news. Click here to subscribe!

Public-private partnership for Big Data in Hematology

HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).